Nanoscale Dynamics of Methylene Blue at the PD-1/SHP2 Interface: Evidence for Non-Specific Protein-Protein Interaction Disruption

The clinical success of monoclonal antibodies targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) has transformed cancer immunotherapy. However, resistance, immune-related toxicity, limited tumor penetration, and prolonged systemic exposure continue to motivate complementary therapeutic strategies. The intracellular recruitment of Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2/PTPN11) to phosphorylated motifs in the PD-1 cytoplasmic tail represents an attractive but pharmacologically challenging point of intervention because it links extracellular checkpoint engagement to T-cell exhaustion. Methylene blue (MB), a clinically used phenothiazinium dye, has been proposed as a small-molecule modulator of the PD-1/SHP2 interaction. Preclinical studies suggest that MB can reduce SHP2 recruitment, restore cytotoxic T-lymphocyte function, and suppress tumor growth. However, characterizing MB as a target-selective immunotherapeutic agent remains uncertain. Pharmacological studies have also reported MB activity against structurally unrelated protein–protein interactions (PPIs), including viral and cytokine-related interfaces, within overlapping low-micromolar ranges. This hypothesis-driven critical narrative review examines the mechanistic biology of the PD-1/SHP2 signalosome and evaluates evidence supporting and challenging MB as a PD-1/SHP2 modulator. Available evidence supports the possibility that MB activity may involve broad physicochemical PPI-interference mechanisms in addition to, or instead of, target-selective PD-1/SHP2 modulation, depending on assay context. Therefore, MB may be useful as a mechanistic probe for intracellular checkpoint modulation, but its classification as a selective PD-1/SHP2 inhibitor requires orthogonal structural, biophysical, and functional validation. Finally, we propose a target-validation framework to distinguish genuine PPI disruption from chemical or assay-related artifacts and to guide the rational development of next-generation small-molecule checkpoint modulators.